Projects

Mgr. Ivana Nemčovičová, PhD.
Research Scientist, Head of Department of Viral Immunology, Marie Curie Fellow

International

Finished
  • CAPSID - Scientific capacity building in biomedical research through scientific exchange and co-development of research services
    Program: European Regional Development Fund (ERDF)
    Duration: 1. 7. 2018 – 30. 6. 2021
  • Biochemical and structural characterization of immune modulators and F-actin capping muscular proteins
    Program: Bilateral - other
    Duration: 1. 9. 2014 – 28. 2. 2015

National

Current
  • -
    Program: VEGA
    Duration: 1. 1. 2026 – 31. 12. 2029
  • Phenomena of viral immunology: CMV for TRICKs or TREAT?
    Program: SRDA
    Duration: 1. 9. 2025 – 31. 8. 2029
  • Immune checkpoint BTLA as a potential biomarker in the therapy of diffuse large B-cell lymphoma
    Program: SRDA
    Duration: 1. 7. 2024 – 30. 6. 2028
  • Antiviral drugs against COVID-19: Design, synthesis and biological activity testing of specific inhibitors of viral proteases of coronavirus SARS-CoV-2
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Biochip systems for targeted glycan analysis of biomarkers for biomedical and biotechnological applications
    Program: SRDA
    Duration: 1. 7. 2021 – 31. 12. 2025
  • New methods of detection of subtypes of selected herpesviruses in patients with hematological malignancies in Slovakia
    Program: PostdokGrant
    Duration: 1. 7. 2024 – 31. 12. 2025
  • The study of HCMV virokine interactions underlying regulation of the immunological synapse for the development of a novel immunotherapeutic concept based on viral tricks
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • Development of a complex in vitro biological evaluation test of newly synthesized antiviral agents against SARS-CoV-2
    Program: DoktoGrant
    Duration: 1. 1. 2024 – 31. 12. 2024
  • Development of bioimmunotherapeutics inspired by viral tricks: TREATing despite the TRICKs
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Molecular immunerecognition of viral UL144 glycoprotein by endogenous signaling molecules and their clinical potential
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • New Antiviral Drugs: Design, Synthesis and Activity Evaluation of Specific Inhibitors of Viral Proteases of Coronavirus SARS-CoV-2
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Immune modulation by cytomegalovirus and its immunotherapeutic potential.
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • IMMUNOVIROLOGICS: Immune modulation by HCMV and its immunotherapeutic potential.
    Program: SASPRO
    Duration: 1. 7. 2015 – 31. 12. 2018
  • Biological and binding properties of clinically significant viral immunomodulators and their immunotherapeutic potential.
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Study of molecular mechanisms of carbonic anhydrase IX regulation and significance of its expression in colorectal cancer.
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
Employees